# Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

> **NCT05611229** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1975 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **COMBINATION_PRODUCT:** Dabrafenib+Trametinib
- **COMBINATION_PRODUCT:** Ipilimumab+Nivolumab
- **COMBINATION_PRODUCT:** Vemurafenib+Cobimetinib
- **COMBINATION_PRODUCT:** Encorafenib+Binimetinib

## Key facts

- **NCT ID:** NCT05611229
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-03
- **Target enrollment:** 1975 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611229, "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05611229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*